Adherence to therapies in patients with type 2 diabetes

Luis-Emilio García-Pérez, María Alvarez, Tatiana Dilla, Vicente Gil-Guillén, Domingo Orozco-Beltrán, Luis-Emilio García-Pérez, María Alvarez, Tatiana Dilla, Vicente Gil-Guillén, Domingo Orozco-Beltrán

Abstract

Adherence to therapy is defined as the extent to which a person's behavior in taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a healthcare provider. Patients presenting with type 2 diabetes mellitus are initially encouraged to maintain a healthy diet and exercise regimen, followed by early medication that generally includes one or more oral hypoglycemic agents and later may include an injectable treatment. To prevent the complications associated with type 2 diabetes, therapy frequently also includes medications for control of blood pressure, dyslipidemia and other disorders, since patients often have more than three or four chronic conditions. Despite the benefits of therapy, studies have indicated that recommended glycemic goals are achieved by less than 50% of patients, which may be associated with decreased adherence to therapies. As a result, hyperglycemia and long-term complications increase morbidity and premature mortality, and lead to increased costs to health services. Reasons for nonadherence are multifactorial and difficult to identify. They include age, information, perception and duration of disease, complexity of dosing regimen, polytherapy, psychological factors, safety, tolerability and cost. Various measures to increase patient satisfaction and increase adherence in type 2 diabetes have been investigated. These include reducing the complexity of therapy by fixed-dose combination pills and less frequent dosing regimens, using medications that are associated with fewer adverse events (hypoglycemia or weight gain), educational initiatives with improved patient-healthcare provider communication, reminder systems and social support to help reduce costs. In the current narrative review, factors that influence adherence to different therapies for type 2 diabetes are discussed, along with outcomes of poor adherence, the economic impact of nonadherence, and strategies aimed at improving adherence.

Figures

Fig. 1
Fig. 1
Number of patients adhering to insulin therapy (frequency) versus percent of the number of days of drug adherence per annum for 1,099 patients with type 2 diabetes mellitus in Scotland; reproduced with permission from Donnelly et al. [28]
Fig. 2
Fig. 2
Dose-taking compliance by frequency of administration per day, using pooled data from published reports included in Claxton et al. [70]. aOnce daily versus three-times daily, P = 0.008. bOnce daily versus four-times daily, P < 0.001. cTwice daily versus four-times daily, P < 0.001. Points show mean and standard deviation

References

    1. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443–453. doi: 10.1016/j.amjmed.2008.09.047.
    1. International Diabetes Federation. Diabetes and impaired glucose tolerance. IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation, 2012.
    1. King DE, Mainous AG, Carnemolla M, Everett CJ. Adherence to healthy lifestyle habits in US adults, 1988–2006. Am J Med. 2009;122:528–534. doi: 10.1016/j.amjmed.2008.11.013.
    1. Vivian EM. Type 2 diabetes in children and adolescents—the next epidemic? Curr Med Res Opin. 2006;22:297–306. doi: 10.1185/030079906X80495.
    1. American Diabetes Association Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36(Suppl 1):S11–S66. doi: 10.2337/dc13-S011.
    1. Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med. 2004;164:1134–1139. doi: 10.1001/archinte.164.10.1134.
    1. World Health Organization: Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497. doi: 10.1056/NEJMra050100.
    1. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47. doi: 10.1111/j.1524-4733.2007.00213.x.
    1. Guillausseau P-J. Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration. Treat Endocrinol. 2005;4:167–175. doi: 10.2165/00024677-200504030-00005.
    1. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028–3035. doi: 10.1161/CIRCULATIONAHA.108.768986.
    1. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003–1008. doi: 10.1007/s00198-004-1652-z.
    1. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–284. doi: 10.1046/j.1464-5491.2002.00689.x.
    1. Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009;44:1640–1661. doi: 10.1111/j.1475-6773.2009.00989.x.
    1. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116. doi: 10.1016/S0895-4356(96)00268-5.
    1. Breitscheidel L, Stamenitis S, Dippel FW, Schöffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper. J Med Econ. 2010;13:8–15. doi: 10.3111/13696990903479199.
    1. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65:314–322. doi: 10.1111/j.1742-1241.2010.02544.x.
    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2012;55:1577–1596. doi: 10.1007/s00125-012-2534-0.
    1. Praet SF, van Loon LJ. Exercise therapy in type 2 diabetes. Acta Diabetol. 2009;46:263–278. doi: 10.1007/s00592-009-0129-0.
    1. Praet SF, van Rooij ES, Wijtvliet A, et al. Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2008;51:736–746. doi: 10.1007/s00125-008-0950-y.
    1. Dunstan DW, Vulikh E, Owen N, Jolley D, Shaw J, Zimmet P. Community center-based resistance training for the maintenance of glycemic control in adults with type 2 diabetes. Diabetes Care. 2006;29:2586–2591. doi: 10.2337/dc06-1310.
    1. Schultz JA, Sprague MA, Branen LJ, Lambeth S. A comparison of views of individuals with type 2 diabetes mellitus and diabetes educators about barriers to diet and exercise. J Health Commun. 2001;6:99–115. doi: 10.1080/108107301750254457.
    1. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14:71–75.
    1. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–1224. doi: 10.2337/diacare.27.5.1218.
    1. Guillausseau P-J. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes: a survey in general practice. Diabetes Metab. 2003;29:79–81. doi: 10.1016/S1262-3636(07)70011-3.
    1. Trinacty CM, Adams AS, Soumerai SB, et al. Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study. BMC Health Serv Res. 2009;9:24. doi: 10.1186/1472-6963-9-24.
    1. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733–735. doi: 10.2337/dc09-1184.
    1. Donnelly LA, Morris AD, Evans JM; DARTS/MEMO collaboration. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100:345–50.
    1. Yurgin NR, Boye KS, Dilla T, Suriñach NL, Llach XB. Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain. Patient Prefer Adherence. 2008;2:87–95.
    1. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772. doi: 10.1016/S0140-6736(09)60697-8.
    1. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239–245.
    1. Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med. 2008;25:850–855. doi: 10.1111/j.1464-5491.2008.02476.x.
    1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393. doi: 10.1056/NEJMoa021778.
    1. Mateo JF, Gil-Guillén VF, Mateo E, Orozco D, Carbayo JA, Merino J. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract. 2006;60:422–428. doi: 10.1111/j.1368-5031.2006.00799.x.
    1. Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care. 2009;47:334–341. doi: 10.1097/MLR.0b013e31818afa1c.
    1. Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44:791–799. doi: 10.1345/aph.1M426.
    1. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26:231–238. doi: 10.1185/03007990903421994.
    1. Dilla T, Costi M, Boye KS, et al. The impact of obesity in the management and evolution of diabetes mellitus. Rev Clin Esp. 2008;208:437–443. doi: 10.1157/13127604.
    1. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2009;19:604–612. doi: 10.1016/j.numecd.2009.03.021.
    1. Terry T, Raravikar K, Chokrungvaranon N, Reaven PD. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2012;14:79–88. doi: 10.1007/s11886-011-0238-6.
    1. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation. 2009;119:351–357. doi: 10.1161/CIRCULATIONAHA.108.191305.
    1. Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26:416–424. doi: 10.1111/j.1464-5491.2009.02696.x.
    1. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11:338–342. doi: 10.1111/j.1463-1326.2008.00973.x.
    1. Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Prac. 2010;87:204–210. doi: 10.1016/j.diabres.2009.11.023.
    1. Broadbent E, Donkin L, Stroh JC. Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients. Diabetes Care. 2011;34:338–340. doi: 10.2337/dc10-1779.
    1. Farmer A, Kinmonth AL, Sutton S. Measuring beliefs about taking hypoglycaemic medication among people with type 2 diabetes. Diabet Med. 2006;23:265–270. doi: 10.1111/j.1464-5491.2005.01778.x.
    1. Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Primary Care Diabetes. 2010;4(Suppl 1):S11–S18. doi: 10.1016/S1751-9918(10)60004-6.
    1. Woudenberg YJ, Lucas C, Latour C. Scholte op Reimer WJ. Acceptance of insulin therapy: a long shot? Psychological insulin resistance in primary care. Diabet Med. 2012;29:796–802. doi: 10.1111/j.1464-5491.2011.03552.x.
    1. Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34:511–517. doi: 10.1177/0145721708317869.
    1. Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008;34:692–697. doi: 10.1177/0145721708320558.
    1. Tiv M, Viel J-F, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS ONE. 2012;7:e32412. doi: 10.1371/journal.pone.0032412.
    1. Doggrell SA. Does intervention by an allied health professional discussing adherence to medicines improve this adherence in type 2 diabetes? Diabet Med. 2010;27:1341–1349. doi: 10.1111/j.1464-5491.2010.03137.x.
    1. Boren SA, Fitzner KA, Panhalkar PS, Specker JE. Costs and benefits associated with diabetes education: a review of the literature. Diabetes Educ. 2009;35:72–96. doi: 10.1177/0145721708326774.
    1. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011.
    1. Ciechanowski PS, Katon WJ, Russo JE, Walker EA. The patient–provider relationship: attachment theory and adherence to treatment in diabetes. Am J Psychiatry. 2001;158:29–35. doi: 10.1176/appi.ajp.158.1.29.
    1. Rubin RR, Peyrot M, Simnerio LM. Health care and patient-reported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29:1149–1155. doi: 10.2337/dc05-2494.
    1. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–1841. doi: 10.1001/archinte.166.17.1836.
    1. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35:1279–1284. doi: 10.2337/dc11-1277.
    1. Dall T, Zhang Y, Chen Y, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff. 2010;29:297–303. doi: 10.1377/hlthaff.2009.0155.
    1. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26:2300–2304. doi: 10.2337/diacare.26.8.2300.
    1. Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care. 2004;27:2616–2621. doi: 10.2337/diacare.27.11.2616.
    1. Hansen RA, Farley JF, Droege M, Maciejewski ML. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. Clin Ther. 2010;32:1308–1319. doi: 10.1016/j.clinthera.2010.07.011.
    1. Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151–173. doi: 10.1108/S0731-2199(2010)0000022010.
    1. Carratalá-Munuera MC, Gil-Guillen VF, Orozco-Beltrán D, et al. Barriers associated with poor control in Spanish diabetic patients. A consensus study. Int J Clin Pract 2013. doi:10.1111/ijcp.12160.
    1. Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36:381–388. doi: 10.1016/j.diabet.2010.03.009.
    1. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33:428–433. doi: 10.2337/dc09-1499.
    1. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48. doi: 10.1186/1471-2261-6-48.
    1. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27:2149–2153. doi: 10.2337/diacare.27.9.2149.
    1. Miccoli R, Penno G, Del Prato S. Multidrug treatment of type 2 diabetes: a challenge for compliance. Diabetes Care. 2011;34(Suppl 2):S231–S235. doi: 10.2337/dc11-s235.
    1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310. doi: 10.1016/S0149-2918(01)80109-0.
    1. Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab. 2009;11:527–533. doi: 10.1111/j.1463-1326.2008.00993.x.
    1. Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–1168. doi: 10.1185/03007995.2011.570745.
    1. Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893–1907. doi: 10.1016/j.clinthera.2008.10.003.
    1. Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012;28:969–977. doi: 10.1185/03007995.2012.684045.
    1. Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabeteic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther. 2012;29:26–40. doi: 10.1007/s12325-011-0096-z.
    1. Dezii CM, Kawabata H, Tran M. Effects of once daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68–71.
    1. Guillausseau PJ. Compliance and optimization of oral antidiabetic therapy: a longitudinal study. Presse Med. 2004;33:156–160. doi: 10.1016/S0755-4982(04)98512-0.
    1. Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. Int J Clin Pract. 2011;65:165–171. doi: 10.1111/j.1742-1241.2010.02513.x.
    1. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–e33.
    1. Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28:1989–1995. doi: 10.1016/j.clinthera.2006.12.011.
    1. Claxton A, de Klerk E, Parry M, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2000;61:928–932. doi: 10.4088/JCP.v61n1207.
    1. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856–861. doi: 10.4065/80.7.856.
    1. Gold DT. Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging. 2011;28:249–255. doi: 10.2165/11586880-000000000-00000.
    1. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144–149. doi: 10.1111/j.1463-1326.2010.01327.x.
    1. Loke YK, Hinz I, Wang X, Salter C. Systematic review of consistency between adherence to cardiovascular or diabetes medication and health literacy in older adults. Ann Pharmacother. 2012;46:863–872. doi: 10.1345/aph.1Q718.
    1. Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. J Res Med Sci. 2011;16:43–49.
    1. Chen CC, Tseng CH, Cheng SH. Continuity of care, medication adherence, and health outcomes among patients with newly diagnosed type 2 diabetes: a longitudinal analysis. Med Care. 2013;51:231–237. doi: 10.1097/MLR.0b013e31827da5b9.
    1. Chu HY, Chen CC, Cheng SH. Continuity of care, potentially inappropriate medication, and health care outcomes among the elderly: evidence from a longitudinal analysis in Taiwan. Med Care. 2012;50:1002–1009. doi: 10.1097/MLR.0b013e31826c870f.
    1. Walker EA, Shmukler C, Ullman R, Blanco E, Scollan-Koliopoulus M, Cohen HW. Results of a successful telephonic intervention to improve diabetes control in urban adults: a randomized trial. Diabetes Care. 2011;34:2–7. doi: 10.2337/dc10-1005.
    1. Morrow DG, Conner-Garcia T, Graumlich JF, et al. An EMR-based tool to support collaborative planning for medication use among adults with diabetes: design of a multi-site randomized control trial. Contemp Clin Trials. 2012;33:1023–1032. doi: 10.1016/j.cct.2012.05.010.
    1. Lin YH, Chen RR, Guo SH, Chang HY, Chang HK. Developing a web 2.0 diabetes care support system with evaluation from care provider perspectives. J Med Syst. 2012;36:2085–2095. doi: 10.1007/s10916-011-9672-7.
    1. Colombo GL, Rossi E, De Rosa M, Benedetto D, Gaddi AV. Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adherence. 2012;6:653–661. doi: 10.2147/PPA.S33968.
    1. Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf. 2008;17:1091–1099. doi: 10.1002/pds.1670.
    1. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43:951–959. doi: 10.1097/01.mlr.0000178216.23514.b7.
    1. Gibson TB, Song X, Alemayehu B, Wang SS, Wadell JL, Bouchard JR, Forma F. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2012;16:589–600.
    1. Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13:846–852. doi: 10.1111/j.1524-4733.2010.00730.x.
    1. Giuffrida A, Gravelle H. Paying patients to comply: an economic analysis. Health Econ. 1998;7:569–579. doi: 10.1002/(SICI)1099-1050(1998110)7:7<569::AID-HEC376>;2-S.
    1. Davidoff A, Lopert R, Stuart B, Shaffer T, Lloyd JT, Shoemaker JS. Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes. Value Health. 2012;15:404–411. doi: 10.1016/j.jval.2012.01.008.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera